Delivery Order SPE2DB20D3303-SPE2DB24FA2DQ

Award Date 8/16/24
Potential Completion Date 8/19/24
Potential Value $1.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a $2,839.26 firm fixed-price delivery order contract to AmerisourceBergen Drug Corporation's Corporate Office division for the supply of 100-count bottles of VYVANSE 40 mg capsules. This order falls under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025, which AmerisourceBergen holds with DLA Troop Support Medical for providing a comprehensive range of pharmaceutical and medical supplies to support...
The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4,563,982,057 units of VYVANSE 50 MG CAPSULE 100S. The award, valued at $2,616.61, has an ultimate completion date of March 18, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, valued at up to $999,999,999.00 through December 31,...
The U.S. government's Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The contract, valued at $6,949.58, is for the delivery of 4,564,090,376 VYVANSE 50 MG CAPSULE 100S. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to AmerisourceBergen Drug Corp by DLA, valued at up to $999,999,999.00 with a performance period through...
The Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a for-profit pharmaceutical distribution company, to provide 4,563,790,909 units of the prescription medication VYVANSE 50 MG CAPSULE 100S. The contract has a potential value of $1,225.88 and a completion date of February 28, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, valued...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 100 units of the pharmaceutical product VYVANSE 50 MG CAPSULE. The contract has a ceiling value of $2,568.66 and a period of performance through April 4, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, which has a potential value of...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of VYVANSE 20 MG CAPSULE 100S. The total ceiling value of the contract is $1,535.33 and the ultimate completion date is April 8, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp with a potential value of up to $999,999,999.00 and a...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, a leading global pharmaceutical distributor. The $1,667.38 contract is to provide 4564222091 VYVANSE 30 MG CAPSULE 100S, a pharmaceutical product, to the agency. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999.00, which serves as the primary...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $1,403.54 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is to provide 4,564,015,246 units of the drug VYVANSE 30 MG CAPSULE 100S. This delivery order is part of a larger, single-award indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp, valued at up to $999,999,999.00 and running through December 31, 2025. The IDC serves as the...
The Defense Logistics Agency (DLA) awarded a Delivery Order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of VYVANSE 50 MG CAPSULE 100S. The firm-fixed-price contract has a ceiling value of $1,020.17 and a completion date of September 19, 2024. This contract is not set aside for a specific socioeconomic program. Amerisourcebergen, through its extensive supply chain capabilities, will provide this critical medication to support various military...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $1,358.10 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4567410765 VYVANSE 30 MG CAPSULE 100S and has a completion date of February 28, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026, which serves as...
  • SPE2DB20D3303
    Indefinite Delivery Contract
  • SPE2DB20D3303-SPE2DB24FA2DQ
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a $1,293.00 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp for the provision of 4565519574 - VYVANSE 50 MG CAPSULE 100S. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of pharmaceutical and medical supplies to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation and is set to be completed by August 19, 2024.

Generated 11/15/24, 9:21 AM